The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …

To date, the choice of therapy for an individual multiple myeloma patient has been based on
clinical factors such as age and comorbidities. The widespread evolution, validation, and …

Despite substantial advances in anti-myeloma treatments, early recurrence and death
remain an issue in certain subpopulations. Cytogenetic abnormalities (CAs) are the most …

Some genetic abnormalities of multiple myeloma (MM) detected more than two decades ago
remain major prognostic factors. In recent years, the introduction of cutting-edge genomic …

Simple Summary Multiple myeloma (MM), a plasma cell neoplasm, is an incurable
hematological malignancy. Gain/amplification of chromosome arm 1q21 (1q21+) is the most …

The prognosis of multiple myeloma is mainly dependent upon chromosomal changes. The 2
major abnormalities driving poor outcome are del (17p) and t (4; 14). However, the outcome …

Certain cytogenetic abnormalities are known to adversely impact outcomes in patients with
multiple myeloma (MM). The phase 3 TOURMALINE-MM1 study demonstrated a significant …

Multiple myeloma (MM) is the second most common hematological cancer and is
characterized by genetic features including translocations, chromosomal copy number …

Elevated inflammatory markers are associated with poor outcomes in various types of
cancers; however, their clinical significance in multiple myeloma (MM) have seldom been …

The detection of cytogenetic abnormalities in multiple myeloma (MM) has received more
importance over last years for risk stratification and the new risk‐adapted treatment …